The reversion of the poor prognostic outcome of CDK12HIGH patients, in response to CMF therapy, to a more favorable disease course similar to that observed in CDK12LOW patients reveals a typical oncogene addiction-like therapeutic vulnerability in CDK12-overexpressing breast cancers. This evidence concerns the gene CDK12 and breast cancer.